Cogenics
     
 
Cogenics
About UsServicesPlace OrdersRegulatory ComplianceMedia InfoContact Us

Cogenics DMET Genotyping Service
Using the Affymetrix DMET panel, Cogenics provides a comprehensive assessment of metabolic and transporter genes, allowing you to use patient genotypes to predict drug response and metabolic profile.

Cogenics provides a full range of genomics services for both research and regulated projects, including a complete genotyping solution, from initial study design, sample collection, genotyping, through data analysis.   

Content
Developed in conjunction with Cogenics, Epidauros, and Eli Lilly, the Affymetrix DMET panel profiles 1,069 drug metabolism biomarkers

  • Phase I Drug Metabolizing Enzymes (e.g. CYPs, ADHs, EPHs, …)
  • Phase II Drug Metabolizing Enzymes (e.g. NATs, UGTs, SULTs, GSTs, …)
  • Drug transport proteins (e.g. ABC transporters, drug uptake transporters, …)
  • Receptors (e.g. ADRB2, CAR, hPXR, …)
  • Includes rare markers with low minor allele frequency (MAF)
  • Others
Core markers analytically validated against 96 sequence validated samples

CYP450s
 
Non-CYP Enzymes
Gene # of Markers   Gene # of Markers
CYP1A2
6
  CDA
2
CYP2A6
7
  DPYD
7
CYP2B6
10
  FMO3
2
CYP2C19
12
  GSTP1
1
CYP2C8
3
  NAT1
12
CYP2C9
10
  NAT2
6
CYP2D6
23
  TPMT
5
CYP2J2
5
  UGT1A1
10
CYP3A4
2
   
CYP3A5
8
   

Transporters
 
Targets
Gene # of Markers   Gene # of Markers
ABCB1 6   VKORC1 9
ABCC2 6      
SLC15A2 4      
SLC22A1 4      
SLC22A2 3      
SLC01B1 9      

DMET is the only product available with comprehensive coverage of all ADME drug metabolism biomarkers, including common and rare variations, insertions, deletions, copy number, triallelic SNPs and pseudogenes.

Cogenics Benefits:

  • Co-Developer of DMET
  • First DMET Commercial Provider
  • Experience processing thousands of DMET arrays
  • GLP-compliant service
  • Data generated in star nomenclature format
  • Rapid turnaround time of 3-5 days

Recent Publications

Request additional information on our DMET Service